Ulcerative Colitis Stocks List

Recent Signals

Date Stock Signal Type
2021-05-06 BHC Stochastic Reached Oversold Weakness
2021-05-06 BHC Calm After Storm Range Contraction
2021-05-06 BHC Lower Bollinger Band Walk Weakness
2021-05-06 BHC Doji - Bullish? Reversal
2021-05-06 FBIO MACD Bearish Centerline Cross Bearish
2021-05-06 FNCH New Downtrend Bearish
2021-05-06 FNCH New 52 Week Low Weakness
2021-05-06 FNCH Spinning Top Other
2021-05-06 FNCH New 52 Week Closing Low Bearish
2021-05-06 HCM Lower Bollinger Band Walk Weakness
2021-05-06 IMUX MACD Bearish Signal Line Cross Bearish
2021-05-06 IMUX Expansion Breakdown Bearish Swing Setup
2021-05-06 IMUX Wide Range Bar Range Expansion
2021-05-06 LABP 20 DMA Resistance Bearish
2021-05-06 LXRX Lower Bollinger Band Walk Weakness
2021-05-06 LXRX MACD Bearish Signal Line Cross Bearish
2021-05-06 LXRX Bollinger Band Squeeze Range Contraction
2021-05-06 MCRB 20 DMA Support Bullish
2021-05-06 MCRB 180 Bullish Setup Bullish Swing Setup
2021-05-06 MCRB Slingshot Bullish Bullish Swing Setup
2021-05-06 PRVB New 52 Week Closing Low Bearish
2021-05-06 PTGX Fell Below 50 DMA Bearish
2021-05-06 PTGX 20 DMA Support Bullish
2021-05-06 VBLT Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-06 VBLT Calm After Storm Range Contraction

Recent News for Ulcerative Colitis Stocks

Date Stock Title
May 7 LXRX Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2021 Results - Earnings Call Transcript
May 7 LXRX Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
May 6 GLPG Galapagos reports Q1 results
May 6 LXRX Lexicon Pharmaceuticals EPS beats by $0.02
May 6 FBIO Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 6 LXRX Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update
May 6 LABP Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease
May 6 GLPG Galapagos refocuses pipeline and rightsizes operations
May 6 PRVB Provention Bio EPS misses by $0.05
May 6 FNCH Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference
May 6 PRVB Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
May 6 IMUX Immunic EPS misses by $0.95
May 6 IMUX Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
May 6 PRVB Earnings Scheduled For May 6, 2021
May 5 BHC Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
May 5 MCRB Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 5 BHC Bausch Health Companies Inc. 2021 Q1 - Results - Earnings Call Presentation
May 5 BHC Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™
May 5 BHC 2 Top Turnaround Stocks to Buy Now
May 4 PTGX Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. Often, symptoms come on slowly and can range from mild to severe. Symptoms typically occur intermittently with periods of no symptoms between flares. Complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer.The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Rates tend to be higher in the developed world with some proposing this to be the result of less exposure to intestinal infections, or to a Western diet and lifestyle. The removal of the appendix at an early age may be protective. Diagnosis is typically by colonoscopy with tissue biopsies. It is a kind of inflammatory bowel disease (IBD) along with Crohn's disease and microscopic colitis.Dietary changes, such as maintaining a high-calorie diet or lactose-free diet, may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission, including aminosalicylates such as mesalazine or sulfasalazine, steroids, immunosuppressants such as azathioprine, and biologic therapy. Removal of the colon by surgery may be necessary if the disease is severe, does not respond to treatment, or if complications such as colon cancer develop. Removal of the colon and rectum can cure the disease.Together with Crohn's disease, about 11.2 million people were affected as of 2015. Each year it newly occurs in 1 to 20 per 100,000 people, and 5 to 500 per 100,000 individuals are affected. The disease is more common in North America and Europe than other regions. Often it begins in people aged 15 to 30 years, or among those over 60. Males and females appear to be affected in equal proportions. It has also become more common since the 1950s. Together, ulcerative colitis and Crohn's disease affect about a million people in the United States. With appropriate treatment the risk of death appears the same as that of the general population. The first description of ulcerative colitis occurred around the 1850s.

More about Ulcerative Colitis
Browse All Tags